2025-10-20 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, presented in English with numerical summaries and analysis.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** JNJ (Johnson & Johnson)
*   **Company Overview:** A multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 48.79%
*   **VOO (S&P 500) Cumulative Return:** 97.05%
*   **Return Disparity:**
    *   Current Disparity: -48.3%
    *   Max Disparity: 16.6%
    *   Min Disparity: -65.5%
    *   Relative Disparity: 21.0%

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period examined. The current return disparity is quite large (-48.3%). The relative disparity of 21.0% indicates that JNJ's performance is near the lower end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
| :----------- | :---- | :---- | :---- | :--- | :----- |
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 336.5  |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1  | 310.8  |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4  | 351.3  |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4  | 379.0  |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5  | 412.0  |
| 2020-2022  | 8.0%  | 79.6% | 9.0%  | 0.4  | 425.4  |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3  | 377.5  |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3  | 348.3  |
| 2023-2025  | 20.0% | 79.6% | -42.0% | 0.1  | 465.3  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Varies significantly, with negative growth in recent periods.
*   **MDD (Maximum Drawdown):** High MDD values, especially recently, indicate significant potential for losses.
*   **Alpha:**  Mostly negative, suggesting underperformance relative to its risk-adjusted benchmark.  The large negative Alpha values in recent periods are concerning.
*   **Beta:** Relatively low, indicating lower volatility than the market.
*   **Cap(B):** Market capitalization shows growth over time, though it has fluctuated.

**2. Recent Stock Price Movement**

*   **Current Price:** 193.22
*   **Previous Close:** 192.12
*   **Change:** 0.57%
*   **5-Day Moving Average:** 191.65
*   **20-Day Moving Average:** 185.98
*   **60-Day Moving Average:** 178.46

**Analysis:** The stock price is currently above its 5-day, 20-day, and 60-day moving averages, which is a bullish signal. The recent price change of 0.57% after previousClose of 192.12 indicates a modest upward movement.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI (Relative Strength Index):** 94.91 (Overbought)
*   **PPO (Percentage Price Oscillator):** 0.1572
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Delta_Previous_Relative_Divergence:** -1.7 (Short-term Decrease)
*   **Expected Return:** -78.1% (Long-term underperformance vs. S&P 500)

**Analysis:**

*   **MRI:** Indicates low investment recommendation.
*   **RSI:** The RSI is very high, indicating that the stock is significantly overbought and a correction may be imminent.
*   **PPO:** Measures the momentum of a stock.
*   **Delta_Previous_Relative_Divergence:** Shows a recent short-term decrease, suggesting weakening relative performance.
*   **Expected Return:** The negative expected return suggests that, based on the model, JNJ is projected to underperform the S&P 500 significantly over the long term (2+ years).

**4. Recent News & Significant Events**

*   **Positive News:**
    *   Subcutaneous amivantamab shows promising results in head and neck cancer.
    *   J&J's Tecvayli-Darzalex combo shows positive results in multiple myeloma trials.
    *   Analyst reports suggest considering "Buy, Sell or Hold" strategies following robust Q3 earnings.
    *   J&J Myeloma Combo Hits Late-Stage Goal.
*   **General Market News:**
    *   S&P 500 posts weekly gain.
*   **Other Corporate News:**
    *   Diorasis Therapeutics appoints new board member.

**Analysis:** The news is mixed.  There are positive developments regarding JNJ's pharmaceutical pipeline, particularly in cancer treatments. However, the mixed analyst sentiment ("Buy, Sell, or Hold") suggests uncertainty about the stock's future performance.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.12 (~Buy)
*   **Opinions:** 23
*   **Target Price:** 198.03 (Average) / 225.00 (High) / 155.00 (Low)
*   **Recent Rating Changes:** No changes indicated.

**Analysis:**  Analysts generally have a positive outlook on JNJ, with a "Buy" consensus and an average target price slightly above the current price. The wide range in target prices (155.00 - 225.00) reflects differing opinions on the stock's potential.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
| :--------- | :--- | :-------- |
| 2025-07-24 | 2.3  | 23.74 B$  |
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2024-07-25 | 1.95 | 22.45 B$  |
| 2025-07-24 | 1.95 | 22.45 B$  |

**Analysis:** Earnings per share (EPS) and revenue have fluctuated over the recent quarters.  The most recent quarter (2025-07-24) shows a revenue of $23.74B.  It's important to analyze trends over a longer period to get a clearer picture.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-06-30 | $23.74B  | 67.87%        |
| 2025-03-31 | $21.89B  | 66.40%        |
| 2024-12-31 | $22.52B  | 68.35%        |
| 2024-09-30 | $22.47B  | 69.01%        |
| 2024-06-30 | $22.45B  | 69.40%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
| :--------- | :-------- | :------ |
| 2025-06-30 | $78.47B  | 7.06%   |
| 2025-03-31 | $78.11B  | 14.08%  |
| 2024-12-31 | $71.49B  | 4.80%   |
| 2024-09-30 | $70.16B  | 3.84%   |
| 2024-06-30 | $71.54B  | 6.55%   |

**Analysis:**

*   **Revenue:**  Revenue has been relatively stable over the past five quarters, with a slight increase in the most recent quarter.
*   **Profit Margin:** The profit margins are very high, indicating strong profitability.
*   **Equity:** Equity has generally increased over the period.
*   **ROE (Return on Equity):** ROE has fluctuated, with a recent decrease.

**7. Overall Summary & Conclusion**

JNJ is a large, established company with strong profitability, as reflected in its high profit margins.  However, several factors suggest caution:

*   **Underperformance:**  JNJ has significantly underperformed the S&P 500, and the expected return is negative.
*   **High RSI:** The high RSI suggests the stock may be overbought in the short term.
*   **Mixed Analyst Sentiment:** While the consensus is "Buy," there is a wide range in target prices, indicating uncertainty.
*   **Alpha & Beta:** The negative alpha values recently suggest underperformance relative to its benchmark, and the low Beta indicates lower volatility than the market.

**Recommendation:** While JNJ has positive aspects (strong profitability, promising drug developments), the underperformance, negative expected return, and overbought condition warrant caution. A potential investor should carefully weigh these factors. Before making any investment decisions, consider consulting with a financial advisor.
